** Shares of drug developer Cytokinetics CYTK.O rise ~3% to $36.24 premarket
** Co reported Q2 revenue of $66.8 million , compared with $0.2 million a year ago, helped by $52.4 million payment related to co's licensing deal for experimental heart disease drug, aficamten, in Japan with Germany's Bayer BAYGn.DE
** Co says it is on track for meeting with U.S. FDA in September ahead of potential U.S. approval of aficamten to treat obstructive hypertrophic cardiomyopathy (oCHM)
** There is "truly palpable excitement and anticipation" for launch of aficamten in early 2026 following potential FDA approval by December 26, H.C.Wainwright analysts say
** oCHM is a condition that makes heart muscles stiff and can cause cardiac arrest
** As of June 30, co had ~$1.0 billion in cash, cash equivalents and investments, CYTK says
** Up to last close, stock down 25% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。